Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. immunehunter

ImmuneHunter SIGNED

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ImmuneHunter project word cloud

Explore the words cloud of the ImmuneHunter project. It provides you a very rough idea of what is the project "ImmuneHunter" about.

breaking    routine    ground    ict    revenues    bioinformatics    radically    ageing    establishing    2020    discovery    antibody    analyzing    technologies    repertoire    mva    platform    deaths    analysed    diagnose    services    diagnostics    entry    accuracy    empower    million    applicable    immune    simultaneously    reduce    signed    full    times    premature    cancer    limited    unable    annual    distinguish    healthy    amounts    mind    disease    status    service    multiplexed    least    sophisticated    2018    discovered    health    unprecedented    companies    discover    contribution    analytical    capacity    demand    superior    biotech    diseases    half    advantage    huge    death    characterization    contracts    small    platforms    grows    mimotope    market    protobios    throughput    signatures    tool    additional    corresponding    clinical    25    format    six    variation    chronic    biomarkers    restricted    overview    pilot    vaccines    scalability    diagnostic    handle    capability    resolution    profiling    detect    illness    tests    molecular    73    therapeutics    data    nearly    competing    figure    causes    applies    healthcare    frequent    heart    spending    patient    accurately   

Project "ImmuneHunter" data sheet

The following table provides information about the project.

Coordinator		 PROTOBIOS OU 

Organization address
address: MAEALUSE 4
city: TALLINN
postcode: 12618
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Estonia [EE]
 Project website http://www.protobios.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2018-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROTOBIOS OU EE (TALLINN) coordinator 50˙000.00

Map

 Project objective

Chronic diseases (cancer, heart and mind diseases) are the leading causes of illness and death. By 2020 their contribution is expected to rise to 73% of all deaths (of which nearly half as premature). To radically reduce the related healthcare spending and contribute to healthy ageing, it is important to diagnose these diseases as early and accurately as possible by analyzing biomarkers. However, the current analytical platforms have been unable to handle the huge amounts of data that need to be analysed for the discovery of new biomarkers, and as a result: (1) only a small number of new biomarkers have been discovered and (2) current routine diagnostic tests are able to provide only a very restricted overview of patient’s health status.

Protobios applies a ground-breaking high-throughput antibody repertoire characterization technology Mimotope Variation Analysis (MVA) to discover new biomarkers, develop novel multiplexed diagnostics, and empower the discovery and development of therapeutics and vaccines. Compared to competing technologies, MVA is superior because (1) it allows to detect and distinguish many different disease signatures simultaneously and (2) the scalability and associated low cost of the MVA process make it applicable for frequent analysis, providing the additional advantage of establishing a robust health assessment tool.

We have used MVA technology to provide clinical diagnostics' development services in a pilot format to a limited number of biotech companies and research institutions. We have witnessed growing demand and signed six-figure contracts for 2018.

The key component of MVA is a sophisticated bioinformatics platform that enables molecular profiling of the immune response at an unprecedented resolution and accuracy. For full-scale market entry, we need to scale up the technical capability of the ICT platform so that the MVA service capacity grows by at least 100 times (corresponding to annual revenues of €20-25 million).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNEHUNTER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNEHUNTER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

JUMPAIR (2018)

Decubitus Ulcers Diseases Diagnoses by means of Smart ICT Anti-Decubitus System based on known Ulcers Activity Biomarkers

Read More  

ClearRing (2018)

An innovative, minimally invasive medical device used for treatment of Benign Prostatic Hyperplasia symptoms.

Read More